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In the case of a release of highly pathogenic bacteria (HPB), there is an urgent need for rapid, accurate, and reliable diagnostics.
MALDI-TOFmass spectrometry is a rapid, accurate, and relatively inexpensive technique that is becoming increasingly impor-
tant in microbiological diagnostics to complement classical microbiology, PCR, and genotyping of HPB. In the present study,
the results of a joint exercise with 11 partner institutions from nine European countries are presented. In this exercise, 10 dis-
tinct microbial samples, among them five HPB, Bacillus anthracis, Brucella canis, Burkholderia mallei, Burkholderia pseu-
domallei, and Yersinia pestis, were characterized under blinded conditions. Microbial strains were inactivated by high-dose
gamma irradiation before shipment. Preparatory investigations ensured that this type of inactivation induced only subtle spec-
tral changes with negligible influence on the quality of the diagnosis. Furthermore, pilot tests on nonpathogenic strains were
systematically conducted to ensure the suitability of sample preparation and to optimize and standardize the workflow for mi-
crobial identification. The analysis of the microbial mass spectra was carried out by the individual laboratories on the basis of
spectral libraries available on site. All mass spectra were also tested against an in-house HPB library at the Robert Koch Institute
(RKI). The averaged identification accuracy was 77% in the first case and improved to>93%when the spectral diagnoses were
obtained on the basis of the RKI library. The compilation of complete and comprehensive databases with spectra from a broad
strain collection is therefore considered of paramount importance for accurate microbial identification.
Highly pathogenic bacteria (HPB) are risk group 3 bacteria,which are defined as biological agents that can cause severe
human disease and present a serious hazard to health care work-
ers. This may present a risk of spreading to the community, but
there is usually effective prophylaxis or treatment available (1). To
this group belong bacteria such as Bacillus anthracis, Francisella
tularensis subsp. tularensis (type A), Yersinia pestis, species of the
Brucella melitensis group, Burkholderia mallei, and Burkholderia
pseudomallei. HPB have the potential to be used in bioterrorist
attacks (2, 3). The Centers for Disease Control and Prevention
(CDC, Atlanta, GA) have classified B. anthracis, F. tularensis, and
Y. pestis as categoryA andBrucella species,B.mallei,B. pseudomal-
lei, and Coxiella burnetii as category B, comprising the main
pathogens of concern for use in bioterrorist attacks (4). These
pathogensmay cause anthrax, tularemia, plague, brucellosis, glan-
ders, melioidosis, and Q fever, respectively. In most parts of the
world, the natural prevalence of these agents is low, even though
some of these agents cause outbreaks in human and animal pop-
ulations from time to time (5–8). The intentional release of these
agents, however, can result in severe public health consequences,
as was shown in the Unites States in 2001 (9, 10). Therefore, ac-
curate assays for microbial identification are important to ensure
proper medical intervention, either in the case of a natural out-
break or an intentional release. Such assays must be able to iden-
tify unambiguously a broad panel of potential threat microorgan-
isms in different background matrices that may or may not be
contaminated with non-HPB bacteria (11).
Matrix-assisted laser desorption ionization–time of flight
(MALDI-TOF) mass spectrometry (MS) is a rapid, accurate, sen-
sitive, and cost-effective method that offers an adequate alterna-
tive to genome-based approaches and that has been widely used
for identification and typing of microorganisms in a clinical rou-
tine setup (12–19), as well as for HPB (20–27). This method does
Received 27 March 2015 Returned for modification 21 April 2015
Accepted 1 June 2015
Accepted manuscript posted online 10 June 2015
Citation Lasch P, Wahab T, Weil S, Pályi B, Tomaso H, Zange S, Kiland Granerud B,
Drevinek M, Kokotovic B, Wittwer M, Pflüger V, Di Caro A, Stämmler M, Grunow R,
Jacob D. 2015. Identification of highly pathogenic microorganisms by matrix-
assisted laser desorption ionization–time of flight mass spectrometry: results of an
interlaboratory ring trial. J Clin Microbiol 53:2632–2640.
doi:10.1128/JCM.00813-15.
Editor: R. Patel
Address correspondence to Daniela Jacob, JacobD@rki.de.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/JCM.00813-15.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.00813-15
2632 jcm.asm.org August 2015 Volume 53 Number 8Journal of Clinical Microbiology
 o
n
 July 23, 2015 by TECH KNO
W
LEDG
E CTR O
F DENM
ARK
http://jcm.asm.org/
D
ow
nloaded from
 
not depend on exclusive consumables and has revealed high levels
of reproducibility in both intralaboratory and interlaboratory
studies (28, 29).Whole cells, crude cell lysates, or bacterial extracts
can be utilized to generate taxon-specific fingerprint signatures
(30). For safety reasons, the application of MALDI-TOF MS for
HPB requires complete inactivation of the microbial samples un-
less the mass spectrometer is operated in a biosafety level 3
(BSL-3) laboratory. As this is often impossible, whole-cell prepa-
rations or crude cell lysates cannot be used for MS-based analyses
of HPB.
In this paper, we describe an international exercise for identi-
fication of HPB by MALDI-TOFMS which was carried out in the
framework of the European Union (EU)-funded project Quality
Assurance Exercises and Networking on the Detection of Highly
Infectious Pathogens (QUANDHIP). The aim of this Joint Action
(JA)was to build up a stabilized consortium that links up 37 highly
specialized laboratories from 22 European countries and to guar-
antee universal exchange of the best diagnostic strategies to sup-
port a joint European response to outbreaks of highly pathogenic
infectious agents. The JA provided a supportive European infra-
structure and strategy for external quality assurance exercises
(EQAE), training, and biosafety/biosecurity quality management.
The aim of this EQAE was (i) to evaluate the current state of the
MALDI-TOF MS-based identification technique for highly
pathogenic agents in Europe, (ii) to explore opportunities to ad-
vance the diagnostic capabilities, including optimization and
standardization of the diagnostic workflow and exchange of stan-
dards and protocols (e.g., for verification of MS-compatible inac-
tivation methods), and (iii) to implement measures to improve
MALDI-TOF MS-based diagnostics of HPB in Europe (capacity
building). The exercise was conducted as a blinded interlabora-
tory study with 10 different bacterial isolates representing five
HPB and five non-HPB test strains and involved in the prepara-
tory-phase pilot tests on non-HPB and inactivation tests with
-irradiated microorganisms. Eleven QUANDHIP project part-
ners from nine European countries participated in this exercise,
including three laboratories from Germany and one each from
Austria, the Czech Republic, Denmark, Hungary, Italy, Norway,
Sweden, and Switzerland.
MATERIALS AND METHODS
Microbial strains and isolates. All microbial strains originated from the
international QUANDHIP strain collection deposited at the Highly
Pathogenic Microorganisms Unit (ZBS 2) at the Robert Koch Institute
(RKI) in Berlin. These strains represent mainly patient isolates sent by the
participating laboratories to the QUANDHIP strain collection. All strains
were characterized twice, first in the laboratories that provided the strains
and second at RKI/ZBS 2 bymeans of a large variety of different methods,
including classicalmicrobiological, PCR-based, and genotypingmethods.
An overview of the strains and isolates used in this study is given in Table
1. All microbial strains and isolates were handled according to the respec-
tive biosafety regulations outlined in Technical Rule for Biological Agents
100 (TRBA 100: Protective Measures for Activities Involving Biological
Agents in Laboratories) (31). HPB and F. tularensis subsp. holarctica (type
B; risk group 2), a very close relative of F. tularensis subsp. tularensis (type
A; risk group 3), were handled according to the requirements of TRBA-
100 in a BSL-3 laboratory. The strains were grown under optimal aerobic
or microaerophilic conditions on Columbia blood agar plates from Ox-
oid, Wesel, Germany (Bacillus spp., Yersinia spp., Burkholderia spp., Bru-
cella spp., andOchrobactrum spp.) or on heart cysteine agar (HCA) plates
(Francisella spp.) for at least 24 h and up to 72 h at 37°C. HCA agar plates
were produced in house from an agar base obtained from Bestbion dx
(Cologne, Germany) and sheep blood (Oxoid). Except for Francisella spe-
cies isolates, all strains were transferred once onto tryptic soy agar (TSA;
VWR, Darmstadt, Germany) or Caso agar (Merck KGaA, Darmstadt,
Germany). Cells were harvested from the second passage by resuspending
colonies in double-distilled water to an optical density at 600 nm of be-
tween 1.0 and 1.2.
Sample preparation/sample inactivation. The concentration of CFU
in the microbial suspensions was adjusted to between 107 and 1010 CFU
per ml (Table 1). The suspensions were stored at 75°C until further
treatment. Inactivation of microbial samples was carried out by means of
high-dose gamma irradiation. For this purpose, microbial suspensions
were sent on dry ice from the RKI to Synergy Health Radeberg GmbH
(Radeberg/Germany) in accordance with the Dangerous Goods Regula-
tions for category A organismswithUN2814 (60). Irradiationwas carried
out according to the recommendations of ISO 11137 (61) using a 60Co
gamma ray source. The measured irradiation dose varied between 27.34
and 32.68 kGy. To minimize the possible radiation-associated spectral
changes (thermal degradation), the samples were transported and irradi-
ated in the frozen state. For this purpose, all samples were shipped along
with a large amount of dry ice. After sample return, it could be verified that
a sufficient amount of dry ice was still present and that the samples were
not thawed at any time. Tests for sterility after irradiation were conducted
by cultivation. In these tests, 10% (vol) of each overall sample solutionwas
added to in-house-produced tryptic soy broth (TSB; Oxoid, Wesel, Ger-
many). Additionally, 100 l of each sample was twice plated onto the
appropriate medium, usually Columbia blood agar or HCA plates (Fran-
cisella). Incubation for growth in TSB was carried out over a time span of
14 days. Final culturing was performed on Columbia blood agar or HCA
plates (Francisella) if visible turbidity of TSB was not observable. All agar
plates were incubated under species-specific ideal conditions for 3 to 7
days. For the EQAE, only samples which showed no growth after gamma
irradiation, either in TSB or on Columbia blood agar or HCA plates, were
used.
The inactivated microbial samples were aliquoted (1 ml) and stored
again at75°C until shipment. The aliquots were shipped to the 11 part-
ner institutions on dry ice. Before shipment, blinded MALDI-TOF MS
test measurements were performed at the Proteomics and Spectroscopy
Unit (ZBS 6) to assess the suitability for MALDI-TOF MS.
When setting up their own spectral databases prior to the ring trial, all
partners could choose among a large variety of procedures, protocols, and
parameters of sample preparation and data acquisition. While some par-
ticipants routinely utilize the so-called direct transfer method (30, 32)
and/or the ethanol-formic acid (FA) protocol recommended by Bruker
Daltonics (30, 33), the group at RKI primarily uses the trifluoroacetic acid
(TFA) inactivation/sample preparationmethod (34). A large advantage of
inactivation by gamma irradiation is that this method is compatible with
TABLE 1 Overview of microbial strains and species used in the
interlaboratory ring trial
Sample Straina Concn (CFU/ml)
1 Burkholderia pseudomallei A101-10 1.1 109
2 Francisella tularensis subsp. holarctica Ft 32 1.7 1010
3 Brucella canis A183-5 1.9 1010
4 Bacillus anthracis AMES 6.4 107
5 Ochrobactrum anthropi A148-11 2.0 1010
6 Yersinia pseudotuberculosis type III 1.3 109
7 Burkholderia mallei A106-3 1.0 109
8 Burkholderia thailandensis E125 5.6 1010
9 Yersinia pestis A106-2 1.3 107
10 Bacillus thuringiensis DSM350 8.6 108
a Escherichia coli RKI A139 and Bacillus cereus BW-B were utilized for -inactivation
test measurements in advance of the ring trial. Bacillus cereus ATCC 10987, Bacillus
thuringiensis DSM 5815, Burkholderia thailandensis DSM 13276, and Yersinia
enterocolitica DSM 4780 were used for pilot tests on non-HPB.
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all of these sample preparation protocols:microbial isolates inactivated by
gamma irradiation can in principle be further processed by utilizing any of
the different laboratory-specific methodologies. This allowed optimal us-
age of in-house spectral databases compiled by the individual partner
institutions prior to the ring trial. The specific details and settings of the
various experimental protocols were polled as a substantial part of the
preparation of the ring trial and are summarized in Table S1 in the sup-
plementalmaterial. Furthermore, the preparation of the exercise included
systematic MS pilot tests of non-HPB strains by each participating insti-
tution. These tests were performed with the aims (i) of identifying and
eliminating possible sources of underperformance, such as inadequate
procedures of sample preparation or poor parameter selection, and (ii)
standardizing, wherever possible, experimental procedures and data ac-
quisition protocols. Within the scope of these pilot tests, MALDI-TOF
mass spectra of Bacillus thuringiensis, Burkholderia thailandensis, Esche-
richia coli, and Yersinia enterocolitica were acquired, shared, and jointly
analyzed.
MALDI-TOF MS. Details of MALDI-TOF MS measurements are in
Table S1 in the supplemental material.
Identification approach A. The analysis of mass spectra from blinded
microbial sampleswas carried out first on-site by the ring trial participants
themselves. In this approach, the participants employed different types of
identification software and utilized a variety of distinct mass spectral li-
braries, such as Bruker’s commercial database for clinical microbiology,
the standard BioTyper database, the so-called Security Relevant reference
library (SR library) from Bruker, the SARAMIS database, and in-house
databases compiled by the institutions themselves (see Table S1 in the
supplemental material). During EQAE’s preparatory stage, some of
the ring trial participants initiated data exchange activities with the
purpose of increasing the size and improving the degree of coverage of
these in-house libraries.
Identification approach B. After submission of the identification re-
sults, all mass spectra were collected at the study center (RKI) and subse-
quently analyzed for a second time using the database of HPB at RKI. This
in-house database consists of 1,118 entries (main spectral projections
[MSPs]), each corresponding to a defined microbial strain from the gen-
eraBacillus,Burkholderia,Brucella, Francisella,Vibrio, andYersinia (along
with a number of clinically relevant species from the genera Escherichia,
Enterococcus, Staphylococcus, Streptococcus, and others). These MSPs rep-
resent database entries in the server component of Bruker’s BioTyper
software package which can be queried via BioTyper software clients (ver-
sion 3.1, build 66; Bruker). Microbial identification was achieved on the
basis of the unmodified standard BioTyper identification method com-
piled by the manufacturer. Furthermore, identification was conducted by
means of logarithmic scores with cutoff values as specified by Bruker: log
score values larger than 2.3 are required for a reliable (highly probable)
identification on the species level, and scores of between 2.3 and 2.0 rep-
resent probable species identification. Scores of between 2.0 and 1.7 point
toward a reliable genus identification, while values below 1.7 are regarded
as unreliable (35). Due to the proprietary nature of the spectral data file
format, analysis in identification approach B was limited to spectra ac-
quired by mass spectrometers produced by Bruker: the BioTyper client
software does not allow importing data in a format other than the Bruker
format. As one of the participating institutions employs MS equipment
produced by Shimadzu (laboratory XI), identification approach B in-
volved the analyses ofMS data from10 of the 11 participating institutions.
Identification approachC. In the third analysis approach, theMatlab-
based software solutionMicrobeMS version 0.72 (24, 36–39) developed at
RKI was used (Matlab; TheMathworks, Inc., Natick, MA). MicrobeMS is
publicly available as Matlab p-code (free of charge) and provides direct
access to Bruker’s raw spectral data and to spectra acquired by the Vitek
MS workflow (formerly SARAMIS, bioMérieux/Shimadzu) via the
mzXML data format (40). The software allows spectral preprocessing,
such as smoothing, baseline correction, intensity normalization, and in-
ternal calibration, and can be employed to produce reference peak
lists from microbial MALDI-TOF mass spectra (39). Furthermore,
MicrobeMS can be used to systematically screen for taxon-specific bio-
markers and for visualization of large spectral data sets (via pseudogel
views). Within the context of the present study, the software was utilized
for identification purposes in combination with the mass spectral data-
base for HPB. This allowed cross-platform analysis of microbial mass
spectra from partner institutions using instrumentation from two differ-
ent manufacturers, Bruker and bioMérieux/Shimadzu (see reference 39
for details).
RESULTS AND DISCUSSION
Gamma inactivation. Complete inactivation of all pathogens
prior to dispatch to the ring trial participants was considered an
essential prerequisite for successful implementation of the inter-
laboratory ring trial. Although it would in principle have been
possible to distribute viable BSL-3 pathogens throughout Europe,
the very strict legal provisions would have represented a signifi-
cant organizational challenge with very high shipment costs. The
shipment of viable BSL-3 samples is only allowed as infectious
material (class 6.2) category A in accordance with the Dangerous
Goods Regulations, whereas inactivated material can be dis-
patched very easily.
As stated earlier, gamma irradiation was selected as the inacti-
vation method of choice. Although the TFA sample preparation
protocol has been specifically developed as a MALDI-TOF MS-
compatible method for microbial inactivation of HPB, it was de-
cided not to employ this protocol. It is well-known that spectra
produced by acid-basedmethods exhibit systematic changes com-
pared to spectra created by the direct transfer method (41). Dif-
ferences between spectra obtained by the ethanol-FA and the TFA
method, however, are much smaller, since both techniques are
ultimately based on acid extraction. In any case, shipment of -in-
activated biological material allowed the partners to choose the
appropriate preparation protocol, which resulted in a very high
degree of compatibility with existing in-house database solutions
at the partner institutions.
High-dose gamma irradiation is known in the literature as a
method suitable for reliably inactivating bacterial pathogens (42,
43) while leaving the primary protein structures basically intact.
Our comparative measurements of pathogenic and nonpatho-
genic microbial strains essentially confirmed the data in the liter-
ature: identification was successful after high-dose gamma irradi-
ation, but irradiation resulted in slightly lower BioTyper log score
values (data not shown). Under the specific experimental condi-
tions at RKI, it was found that the signals relevant for identifica-
tion remained very marked after gamma irradiation, though with
reduced peak intensities. The MALDI-TOFmass spectra of E. coli
and B. cereus exemplarily demonstrate the presence of all of the
main peaks in both the irradiated and the reference samples (Fig.
1). However, the spectra of the -inactivated samples generally
exhibited a lower signal-to-noise ratio due to the slightly reduced
peak intensities.
Pilot tests on non-HPB strains. Pilot tests were conducted by
the partners to identify factors that affect the overall performance
of the MS-based identification technique and to standardize ex-
perimental procedures, data acquisition protocols, and methods
of spectral analysis. In the context of the preparation of the pilot
tests, experimental methods and parameters were polled (see Ta-
ble S1 in the supplemental material).
The jointly conducted analysis ofmicrobialMALDI-TOFmass
spectra from non-HPB revealed a number of peculiarities, such as
Lasch et al.
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broadened peaks, spectrum baseline irregularities (elevated base-
lines), and the appearance of additional satellite peaks in some of
the microbial mass spectra. While peak broadening and baseline
elevation effects could be identified relatively easily as a result of
the application of excessive laser power (see reference 44), it was
more challenging to identify the sources and causes of additional
satellite peaks.
Satellite peaks. In Fig. 2, the bottom panel illustrates a first
example of satellite peaks in amass spectrumofB. thuringiensis. As
shown, additional peaks such as are described above occurred at
16-Da intervals at higher molecular masses with respect to the
parent peak (cf. peak series at m/z 4,335, 4,351, and 4,367). The
spectrum of B. thuringiensis obtained by the reference sample
preparation method (TFA inactivation) clearly demonstrates
FIG 1 MALDI-TOF mass spectra of control samples (black traces) and microorganisms inactivated by means of high-dose gamma irradiation (red traces).
Irradiated samples of E. coli A139 and B. cereus BW-B (spores) were prepared for MALDI-TOFMS in the same way as the retained control samples, by means of
the TFA inactivationmethod (34). The spectra (smoothed and baseline corrected) demonstrate only insignificant differences between the irradiated and control
samples, suggesting that gamma irradiation is compatible with the routine sample preparation protocols used by the partner institutions (see the text for details).
Intens. [a.u.], intensity in arbitrary units.
FIG 2 Oxidation of Bacillus thuringiensis microbial extracts by sodium hypochlorite (NaClO). Top, reference mass spectrum of a B. thuringiensis sample
prepared on the basis of the trifluoroacetic acid (TFA) inactivation technique (34). Bottom, TFA-treated sample of the same Bacillus strain with likely contam-
ination by sodium hypochlorite. The spectral differences—satellite peaks at16-Da intervals—are attributed to contamination by the oxidant NaClO, which
was employed for external sterilization of sample vials during outward transfer from a BSL-3 laboratory (spectra were smoothed and baseline corrected; see the
text for further details).
Interlaboratory MALDI Ring Trial
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the absence of such peaks in the control measurements (Fig. 2,
top). The observed satellite peaks are most likely caused by the
action of sodium hypochlorite (NaClO), which is known as an
effective disinfectant and a strong oxidizing agent. Because of its
well-known antimicrobial and sporicidal properties, NaClO was
applied in the laboratory of one of the partners for 15 min in a
concentration of 10% (vol/vol) for external sterilization of the
MALDI-TOF MS sample vials. It seems likely that during this
period, small amounts of NaClO entered the tubes, e.g., via in-
completely closed lids. In proteins, the amino acid methionine
and aromatic residues like tryptophan and tyrosine are potential
first oxidation targets (45, 46). In the case of oxidation of methi-
onine, the experimentally observed mass differences between the
parent and satellite peaks of 16 Da would fit well with the com-
putedmasses of unoxidizedmethionine andmethionine sulfoxide
as the singly oxidized species (47). However, the mass differences
mentioned would be also observable in the case of oxidation of
other amino acids.
Similar oxidation-induced satellite peaks (m/z of 16 Da)
were observed when microbial samples were accidentally inocu-
lated with another sterilizing agent, peracetic acid (PAA). PAA
also acts as an oxidizing agent and can cause the oxidation of lipids
and amino acid side chains of peptides and small proteins in mi-
crobial extracts (data not shown).
Satellite peaks were also detected in samples prepared by
means of the ethanol-FA sample preparation protocol (30, 33).
Using the examples of spectra from B. cereus ATCC 10987 and B.
thuringiensis DSM 5815, the traces in Fig. 3 show the presence of
additional peaks at a distance of 28 Da: the black curves denote
mass spectra in them/z 6,250-to-7,500 region of Bacillus samples
prepared by the TFA inactivation method, while the red spectra
were obtained from identicalBacillus strains prepared bymeans of
the ethanol-FA sample preparation method, which included in-
cubation in 70% FA (vol/vol) for 30 min. Both pairs of spectra
display parent peaks at m/z 6,695 (B. cereus) or m/z 6,711 (B.
thuringiensis), assigned as a beta-type small, acid-soluble protein
(-SASP), m/z 6,835 (	-SASP), and m/z 7,082 (	--SASP) (see
references 24 and 48 for peak assignments). Apart from these
dominating signals, the spectra of FA-treated samples exhibit ad-
ditional satellite peaks at m/z 6,723 (B. cereus) or m/z 6,739 (B.
thuringiensis) and at m/z 6,863 (both strains). Satellite signals are
found at a distance of 28 Da from the parent peaks, typically
with intensities of less than 20% of the original signal. A likely
explanation for the occurrence of satellite peaks would be chemi-
cal modification of the SASPs (formyl esterification) due to pro-
longed sample treatment by FA. FA treatment has been associated
with formylation of proteins in microbial extracts (49), with the
specific targets of serine and threonine residues. Furthermore, it is
known that formylation is particularly effective when highly con-
centrated FA is applied to small hydrophobic proteins (50), such
as SASPs. Since each additional satellite peakmay potentially have
a negative impact on the performance of the identification algo-
rithm, the exposure time to FA should be minimized whenever
possible. Taking into account that this note is also given in the
BioTyper manual (see reference 35), the reduction of FA incuba-
tion time is considered an important measure for improving the
accuracy of identification.
Results of the interlaboratory ring trial. Table S2 in the sup-
plemental material has a summary of the identification results in
the context of identification approach A. This approach involved
data analysis on site by each partner institution. The table not only
shows an overviewof the results of the blinded identity tests, it also
provides either the logarithmic BioTyper scores or, alternatively,
the respective SARAMIS score values. In approach A, MALDI-
TOF mass spectra acquired by laboratory XI were analyzed twice,
first by using customized in-house algorithms and second by an
analysis carried out elsewhere bymeans of the SARAMIS software
and the database solution fromAnagnostec. For this reason, Table
S2 includes an additional columnheaded “Laboratory XII,” which
is different from identification approaches B and C.
The color scheme used in Table S2 is a traffic light coloring
scheme: it uses the colors green for correct, yellow for partially
correct, and red for false identification results. A correct result was
obtained when the identity was accurately revealed at the genus,
species, and subspecies levels. Cells colored yellow denote identi-
fication results which were either incomplete—for example, in
cases where the subspecies specification was lacking (see sample 2,
F. tularensis subsp. holarctica, in Table S2)—or where the genus
assignment was correct but the species was left unassigned (e.g., in
lines 9 and 10, laboratory VIII, Yersinia sp. and Bacillus sp., in
Table S2). Furthermore, a result was also considered partially cor-
rect in cases of contradictory identification results, i.e., if different
FIG 3 Formylation of spore marker proteins (small, acid-soluble proteins
[SASPs]) in test samples of Bacillus cereus and Bacillus thuringiensis possibly as
a result of prolonged treatment by highly concentrated (70%) formic acid (FA)
(24).Hashmarks (#) indicate peaks atm/z 6,695 or 6,711 corresponding to two
possible variants of -SASP in B. cereus and B. thuringiensis. Ampersands (&)
indicate peaks at m/z 6,835 (	-SASP in B. cereus ATCC 10987; UniProt
Q73CW6). All mass spectra were smoothed, baseline corrected, and intensity
normalized. Black traces are reference MALDI-TOF mass spectra of Bacillus
samples prepared by the TFA inactivation method (34). Red traces are spectra
from identical strains processed by the ethanol-FAmethod (33). Red numbers
denote additional mass peaks at a distance of 28 Da with reference to the
	-SASP (m/z 6,835) or the -SASP (m/z 6,695/6,711) peaks.
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microbial identities were obtained from spectra of technical rep-
licate measurements. In such cases, however, at least one result
had to be correct. An example of contradictory identification re-
sults can be found in Table S3 for sample 6 from laboratory X.
Score values in this or similar instances were indicated by a range
of values. Identification results were considered incorrect (red
cells) if either an HPB was clearly assigned as a non-HPB (false
negative) or, alternatively, if a non-HBP was identified as an HPB
(false positive). Cases where no false-positive/false-negative re-
sults were obtained, for example, if a result was inconsistent or
unavailable (no spectrum), were also regarded as partially correct
(no confirmation, but also no all clear). To calculate the overall
accuracy index of the entire identification approach, a point sys-
tem was introduced, giving one point for each correct identifica-
tion result (green). Furthermore, cells with partially correct results
(yellow) received half points, while no points were given for in-
correct results (red). All points were then summed over the entire
table; the sums were subsequently divided by the number of cells
of each table. The quotient thus determined was finally multiplied
by 100 and expressed as a percentage. To exclude an undue
weighting of the measured data from laboratory XI, the point
values from the rows “Laboratory XI” and “Laboratory XII” were
averaged before summation in identification approach A.
The overall identification accuracy of identification approach
A was 77% (see Table S2 in the supplemental material). While the
accuracy of identification of samples 1 (B. pseudomallei), 4 (B.
anthracis), 5 (Ochrobactrum anthropi), 7 (B. mallei), 8 (B. thailan-
densis), and 9 (Y. pestis) was relatively high, there were major
problems when diagnosing samples 2 (F. tularensis subsp. holarc-
tica), 3 (Brucella canis), 6 (Yersinia pseudotuberculosis), and 10 (B.
thuringiensis). Furthermore, the results from laboratory IX were
generally difficult to assess. In this laboratory, diagnoses were
made only on the basis of the standard BioTyper database for
clinicalmicroorganisms; neither an in-house database ofHPBnor
the SR library from Bruker were available to this partner (cf. Ta-
bles S1 and S2).
The overall identification results improved significantly when
spectra of the interlaboratory exercise were tested against the da-
tabase of highly pathogenicmicroorganisms compiled at RKI over
the past 10 years; the overall identification accuracy improved
from77.0% in approachA to 93.5% in approachB (see Table S3 in
the supplemental material). The improvements were particularly
striking in the cases of samples 2 (F. tularensis subsp. holarctica), 3
(B. canis), and 10 (B. thuringiensis). However, differentiation be-
tween samples 6 (Y. pseudotuberculosis) and 9 (Y. pestis) improved
only slightly in approach B.
In the third approach, identification approach C, the overall
picture did not differ much from approach B (see Table S4 in
the supplemental material). The minor improvement in the
overall identification accuracy (93.7%, compared to 93.5%) is
statistically insignificant, which is not particularly surprising:
although both approaches involved different software imple-
mentations with different algorithms, they relied on an identi-
cal spectral database. The results given in Table S4 demonstrate
a decreased identification rate for sample 7 (B. mallei) and a
slight improvement for sample 6 (Y. pseudotuberculosis). How-
ever, themajor advantage of approach C over approach B consists
in the fact that it allows analysis of spectra obtained by means of
the bioMérieux/Shimadzu system (cf. rows “Laboratory XI” of
Tables S3 and S4). Due to missing import capabilities for Shi-
madzu-specific spectral files in the BioTyper software, the data
acquired by laboratory XI may be analyzed by approach C but
not using the BioTyper software employed in identification ap-
proach B.
Figure 4 shows a summary of the results of all identification
approaches. This table again illustrates the improvements of the
FIG 4 Summary of the different identification results from the MALDI-TOF MS ring trial, with the numbers of correct, partly correct, and incorrect identifi-
cations, as well as point scores for identification (correct identification, one point; partly correct, half a point; incorrect, zero points) and the corresponding
identification accuracy values (percentages). Green, identification accuracy for the givenmicrobial strain is equal to or greater than 90%; yellow, accuracy is equal
to or greater than 75% and below 90%; red, accuracy is below 75%.
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identification accuracies in approaches B and C in comparison to
those of approach A, particularly for samples 1 to 4 and 10. With
regard to samples 2 (F. tularensis subsp. holarctica) and 3 (B. ca-
nis), we assume that the relatively high error rates in approach A
derive from incomplete or missing spectral entries for both sub-
species/species in the SR BioTyper library extension. We have
noted that identification of F. tularensis subsp. holarctica and of B.
canis was incomplete in cases where identification was made by
means of this particular database extension. A closer examination
of the SR database content revealed the absence of subspecies in-
formation in entries for F. tularensis (sample 2) and the lack of
spectral entries for Brucella species other than B. melitensis (sam-
ple 3).
In contrast, it was interesting to note that the sophisticated
software algorithms employed in approaches B and C can cause
problems even in cases where extensive spectral databases are
available. To give an example, differentiation between Y. pseudo-
tuberculosis and Y. pestis by approaches B and C is far from being
ideal (cf. samples 6 and 9 in Tables S3 and S4 in the supplemental
material). To a certain extent, this could be caused by the low
initial concentration of Y. pestis in the sample solution (1.3 107
CFU/ml) (Table 1). Several ring trial participants have indeed re-
ported a relatively poor signal-to-noise ratio inMALDI-TOFmass
spectra acquired from aliquots of sample 9. Low spectral quality is
certainly a factor which makes differentiation of Y. pestis and Y.
pseudotuberculosis difficult. An even more important factor, how-
ever, is the very high degree of similarity of spectra from these two
very closely related species. In fact, Y. pestis is known as a clone of
Y. pseudotuberculosis which has only recently evolved from Y.
pseudotuberculosis (51, 52). Both species share genomic sequences
and have identical 16S rRNA genes (53). As a consequence, their
differentiation by MALDI-TOF MS is challenging; it has been
found that differentiation can be carried out only on the basis of a
singlemass peak atm/z 3,065 (36, 38). This peak has been assigned
to a fragment of the plasmid-encoded (pPCP1) Pla protein.
Therefore, MS-based differentiation is possible only for strains of
Y. pestis carrying the pPCP1 plasmid. At this point, it should be
stressed that visual inspection of the mass spectra would have
helped in solving the particular problem of differentiatingY. pseu-
dotuberculosis and Y. pestis. Although the biomarker for Y. pestis at
m/z 3,065 is typically very intense, pattern recognition routines do
not always provide reliable results in cases when the outcome of
the identification is based on the presence or absence of only a
single biomarker. Following this line of reasoning, the supervised
modeling approach chosen by laboratory XI, which relies on 15
biomarkers to discriminate between Y. pestis, Y. pseudotuberculo-
sis, and Y. enterocolitica, may provide the basis for a more robust
typing scheme (54).
In the present study, problems also occurred when differenti-
ating the closely relatedmembers of theB. cereus group,B. anthra-
cis,B. cereus, andB. thuringiensis. First, we have no information on
whether MALDI-TOF MS allows reliable differentiation of B. ce-
reus and B. thuringiensis. Our own observations, however, re-
vealed that strains from both species are frequently identified
based on their strain-specific spectral profiles. On the other hand,
mass spectra ofB. anthracis strains exhibit a specific-SASP signal
atm/z 6,679 (22, 24, 55–58) that is usually not present in spectra of
other B. cereus group members. However, in the recent literature,
there is increasing evidence that spectra of certain strains of B.
cereus and B. thuringiensis may also exhibit -SASP peaks at m/z
6,679 (59) (see also the spectrum of B. cereus BW-B in Fig. 1).
Therefore, this -SASP biomarker is not necessarily pathogno-
monic for B. anthracis. Furthermore, we and others have noted
that the second published biomarker of B. anthracis, atm/z 5,413
(24), is often found in spectra of B. cereus and B. thuringiensis also.
Both facts should be considered when assessing the identification
results for B. cereus group members: the results of MALDI-TOF
MS should not form the sole basis for potentially far-reaching
decisions; for example, in the event of suspected intentional re-
lease of B. anthracis.
Conclusions. This paper reports on an interlaboratory exter-
nal quality assurance exercise (EQAE) conducted by 11 partner
institutions from nine European countries. In this ring trial,
MALDI-TOF MS was used as a tool for rapid, reliable, and cost-
effective identification of highly pathogenic microorganisms. In
the preparatory phase of the exercise, pilot tests on nonpathogenic
strains were carried out in order to optimize and standardize the
experimental procedures at the partner institutions and to iden-
tify possible sources of underperformance. Irradiation by gamma
rays proved to be a MALDI-TOF MS-compatible inactivation
method which induced only subtle spectral changes with negligi-
ble influence on the quality of the diagnosis. In the ring trial, the
average identification accuracy was 77%when using nonstandard
mass spectral databases. The accuracy improved to 
93% when
spectral diagnoses were reached on the basis of an optimized spec-
tral database with better coverage of highly pathogenic and related
species.
The present EQAEhas highlighted current strengths andweak-
nesses of the MALDI-TOF MS-based approach for identification
of HPB and has confirmed the need for high-quality spectral da-
tabases to facilitate improved identification accuracy. Experiences
gathered from the present international EQAE also suggest that, as
long as high-quality and comprehensive spectral databases are
available, different preparative procedures, the degree of user ex-
perience, and different types of instrumentation and analysis soft-
ware are not likely to critically affect identification of HPB. The
compilation of complete and comprehensive databases is thus
considered to be of paramount importance for reaching accurate
and reliable spectral diagnoses. Future efforts to improve the di-
agnostic capabilities should therefore focus on the exchange of
validated reference spectra. We are confident that further ring
trials will confirm the improvements achieved by such activities.
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